Mammoth Biosciences is a biotechnology company focused on leveraging its proprietary ultracompact CRISPR systems to develop long-term curative therapies, as well as other applications such as decentralized precision diagnostics. Founded by CRISPR pioneer and Nobel laureate Jennifer Doudna and Trevor Martin, Janice Chen, and Lucas Harrington, the company’s ultracompact proteins are designed to enable in vivo gene editing in difficult to reach tissues utilizing both nuclease applications and new editing modalities beyond double stranded breaks, including base editing, gene writing, and epigenetic editing.
We have a unique investment opportunity that is out side of the typical stages we offer our members. Mammoth Biosciences is an existing syndicate company in which we have invested $2.5M across three priced rounds as we have watched the Company's progress over several years. Because of our relationship with the Company and the support and advice we have provided,Mammoth has reserved an allocation for Plum Alley in the current Series D round which is generally only open to institutional-type investors. In order to meet a compressed timeline, we are unable to provide the customary Plum Alley materials for an investment opportunity. However, the Company-provided confidential deck is provided below for your review.
Mammoth is in the midst of closing on $150M in anew capital round led by Redmile Group at a $950M pre-money valuation. TheCompany has completed a first close of $120M with participation from Redmile, Senator Fund, Green Spring and others. The balance of the round is being made available to select investors via a second close targeted for Monday, August, 9th. Plum Alley was able to secure an allocation of $1.5 million in this second close. This allocation will be equally distributed between Plum Alley member investors and the PA fund, with each investing $750k. We are operating on the compressed timeline and request your commitment amount by filling out the form below by this Friday, August 6th, 2021(end of day).
This is a special opportunity for Plum Alley members who did not previously participate in the Mammoth Syndicate. We will prioritize commitments from existing investors in Mammoth that invested viaPlum Alley Syndicate XII, and then accommodate new member commitments. In the event of oversubscription, we will first take in all existing investor commitments, then pare back syndicate members evenly as needed. If this occurs and you are a new investor interested in participating in this capital raise, please email us here.
Special Investment Opportunity:
The Company has achieved rapid progression ingrowing its IP strategy and establishing itself as a CRISPR platform across both therapeutics and diagnostics. It has secured large global pharmaceutical customers and established partnerships with GSK, Horizon, Hamilton, Agilent andMillipore Sigma. Given recent market dynamics, the Company may be in position with this round to execute on its goal of realizing an exit in the next year or two. The Mammoth Biosciences team includes Dr. Jennifer Doudna, a pioneer in the field of CRISPR technology and a recent Nobel Laureate, as their scientificCo-Founder. Dr. Doudna, along with Trevor Martin, Lucas Harrington and JaniceChen, co-founded Mammoth Biosciences and developed a first-to-market, novel platform building the next generation of CRISPR tools for diagnostic and therapeutic applications. Mammoth offers a unique value proposition in its breadth of potential applications, and has a significant competitive advantage towards building a CRISPR platform for next-generation use cases.
Other investors in the Company include MayfieldFund, Decheng Capital, Verily Life Sciences (Google's life sciences venture arm with over $1B AUM), Brook Byers (founder of Kleiner Perkins with over $5B AUM),NFX, 8VC, Amazon and others.
Important Information and Timeline:
In order to participate in the second close, we need all final commitments by Friday,August 6th, 2021(end of day).
We are also hosting a call on Friday, August 6th at 12pm ET // 9am PT to answer questions.
Please note we are not able to accommodate individual questions over email. We encourage you to join the call on Friday where we willbe happy to address final questions. Plum Alley's customary syndicate company expense and investment carry will apply.
Regards,
The Plum AlleyInvestment Team
.png){kind=logo}